McKee Amy E 4

What Happened
Director Amy E. McKee was issued 642 shares of BioCryst Pharmaceuticals (BCRX) common stock on 2026-02-27 at a reported price of $8.75 per share, valued at $5,618. The issuance is coded as an award/acquisition (A) — equity compensation rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-27; Form 4 filed: 2026-03-03 (filing appears late under the 2-business-day rule).
• Price / value: 642 shares × $8.75 = $5,618 (rounded).
• Reason: Shares issued in lieu of 50% of the quarterly cash board retainer of $11,250 (footnote F1).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Transaction code: A (award/grant/acquisition); not a sale or option exercise.

Context
This was a routine director compensation issuance (equity in lieu of cash retainer). Such awards reflect compensation choices and do not, by themselves, indicate the insider is buying or selling stock for investment reasons. The late filing (if confirmed) is an administrative compliance issue rather than a market signal.